Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Agios Pharma (AGIO) to report data from Phase 1 study of AG-519 in patients with PK deficiency in at European Hematology Association Meeting

Source Link:: http://seekingalpha.com/article/3908036-agios-pharmaceuticals-agio-ceo-david-schenkein-q4-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

AGIO

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The purpose of the study is to investigate a drug called AG-519, which is being developed for the treatment of a disease called pyruvate kinase deficiency (also known as PK deficiency) and other forms of anemia. This study is a 3 part study with Part 1 enrolling healthy volunteers into single ascending dose (SAD) groups, Part 2 enrolling healthy volunteers into multiple ascending dose (MAD) groups and Part 3 enrolling healthy volunteers to investigate how much of the study drug is taken up by the body and how food affects the uptake of a prototype formulation of AG-519.

https://clinicaltria...

Additional Relevant Details Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers:

- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -- Robust Dose-Dependent Changes in ATP and 2,3-DPG Blood Levels Observed Consistent with PKR Enzyme Activation -

http://investor.agio...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 20, 2016

Occurred Source:

http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-newsArticle&ID=2176575

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Interim Data, Phase 1 Data, Ag-519, Pyruvate Kinase Deficiency, Pk Deficiency, European Hematology Association, Double Blind